MBX

MBX Biosciences, Inc.

BS score 35.6LOWPHASE1 · mkt cap $1.56B · rev ttm $0

drug hypothesis

MBX 1416 modulates Unknown - not disclosed in available data to treat Postbariatric Hypoglycemia.

moa:Unknown - not disclosed in available filing data. Appears to be an investigational therapy for postbariatric hypoglycemia based on trial indication.

score breakdown

trial design20

base rate disconnect39

language red flags60

composite35.6

valuation analysis

market cap$1.56B

revenue ttm$0

phasePHASE1

historical base rate8%

disconnect ratio1.3x

lead trialNCT06036784

meta

cik0001776111

first discovered2026-04-09

last updated2026-04-10

statusACTIVE

llm model—

extracted at2026-04-10

trial design

Phase 1 randomized, double-blind, placebo-controlled study in healthy subjects. Three-part design (Part A, B, C). Enrollment: 69 subjects.

primary endpoint:Number of participants with adverse events (AEs) and Serious Adverse Events (SAEs) through Day 29 (Part A), Day 45 (Part B), or Day 21 (Part C)

claimed differentiation

Cannot determine - SEC filing business section content not provided

language red flags

CRITICAL: SEC filing business section contains no substantive content - only a '1' appears to be present
Unable to assess claims, risks, or differentiation statements due to missing filing data
Trial data alone insufficient to evaluate investment thesis without SEC filing context